Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

7 (6%) ====== ====== ====== ====== NOTES: - GAAP net sales for the three months ended June 30, 2009 totaled $4.6 billion, down 6 percent as compared to 2008, reflecting operational growth of 4 percent and an unfavorable impact from foreign exchange of 10 percent. - GAAP net sales for the six months ended June 30, 2009 totaled $9.0 billion, down 6 percent as compared to 2008, reflecting operational growth of 4 percent and an unfavorable impact from foreign exchange of 10 percent. Additional information about U.S. and international sales for specific products is available by calling the company or visiting the Investor Relations Web site athttp://ir.schering-plough.com. 

    SCHERING-PLOUGH CORPORATION

    Reconciliation of Non-U.S. GAAP Financial Measures

    Adjusted net sales, defined as Net sales plus an assumed 50 percent of
    global cholesterol joint venture net sales.


    (Dollars in millions)                       Three months ended June 30,
                                                       (unaudited)
                                                       -----------
                                              2009          2008      %
                                              ----          ----      -

    Net sales, as reported                  $4,647        $4,921      (6%)

    50 percent of cholesterol joint venture
     net sales  a/                             509           566     (10%)
                                               ---           ---     ----

    Adjusted net sales                      $5,156        $5,487      (6%)
                                            ======        ======      ===


                                                Six months ended June 30,
    (Dollars in mi
'/>"/>
SOURCE  Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9